Immuron Ltd

IMC

Company Profile

  • Business description

    Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

  • Contact

    Chapman Street
    Unit 10, 25-37
    Blackburn North
    MelbourneVIC3130
    AUS

    T: +61 398245254

    https://www.immuron.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    7

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,374.0082.20-0.97%
CAC 407,736.9133.57-0.43%
DAX 4023,159.9073.250.32%
Dow JONES (US)41,317.43564.471.39%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,977.73266.991.51%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,421.2593.360.76%
S&P 5005,686.6782.531.47%
S&P/ASX 2008,157.8080.20-0.97%
SSE Composite Index3,279.037.62-0.23%

Market Movers